Growth of the proteomics array markets is highly dependent on the adoption and advantageous employment of proteomics arrays in a mid-density and high-density format. Mid-density multiplexed immunoassays will likely be used for the validation of hypothesis-driven studies, supplanting the need for single-plexed technologies, such as ELISA or western blots. High-density proteomics arrays will likely be utilized for the majority of large-scale discovery efforts, including the analysis of native proteins or protein-protein interaction analyses.
New analysis from Frost & Sullivan Drug Discovery Technologies research (drugdiscovery.frost.com) reveals that U.S. Proteomics Array Markets earned revenue of $51.6 million in 2005 and estimates to reach $344.3 million in 2012.
If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants an overview of the latest analysis of the U.S. Proteomics Array Markets, then send an email to Melina Trevino, Corporate Communications at melina.trevino[.]frost.com with your full name, company name, title, telephone number, fax number and email. Upon receipt of the above information, an overview will be sent to you by e-mail.
"With greater sensitivity and improved content selection, mid-density and high-density proteomics arrays are reaching new technological heights," notes Research Analyst Jonathan Witonsky. "With further technological advancements and the identification of additional valuable content, it is expected that the revenue generated from the sales of these proteomics arrays will be a significant component of the overall proteomics array markets."
Technological advancements made to proteomics arrays, combined with research success stories, will likely provide the impetus to the proteomics array market that will allow it to undergo its most robust growth. Currently, there is skepticism regarding the achievable antibody specificity with high-density antibody arrays. Furthermore, researchers are waiting for more success stories regarding biomarker discovery and pathway characterization with functional protein arrays. It is expected that impending technological innovations made to proteomics array technology, combined with increased content selection and publicized success stories, will provide the proteomics array markets with exceptional growth beginning in the next three to five years.
“The potential transition of numerous researchers from traditional single-plexed technologies, such as ELISAs or western blot, to a multiplexed format has the potential be a significant driver to the proteomics array markets," says Frost & Sullivan Research Analyst Jonathan Witonsky, "however, many of these researchers are hesitant to invest in proteomics array technologies given the insufficient selection of content and panel menus."
Numerous researchers are reluctant to make the capital investment required to bring proteomics array technologies into their laboratories because of the current limitations to content selection or panel menus. Researchers demand that more disease-specific, organ-specific, or organism-specific panels come available before they are willing to transition for proven single-plexed methods. The proteomics array platform that is proven compatible with the largest menu of content will have the greatest success.
“Proteomics array suppliers need to from strategic partnerships and high-profile research collaborations with the developers and providers of valuable proteomics content,” notes Witonsky. “The proteomics content generated, catalogued, and validated by these research and industry leaders can be utilized by the proteomics array suppliers for the development of innovative proteomics arrays that will significantly enable the research community.”
In the near term there will be tremendous value associated with technology platforms that can be customizable based on the content of interest to the end user. As the knowledgebase with regard to specific tissue types and the human proteome increases, the demand for arrays that encompass predefined content will increase. There exists a natural synergy between content developers or providers, who have extensive knowledge and IP with respect to proteomics content and assay development, and proteomics array providers, that have a solid surface chemistry and technology platform. While the market has already seen numerous partnerships form, additional opportunities exist that could serve to produce a truly value added comprehensive package for suppliers in multiple proteomics array markets.
U.S. Proteomics Array Markets, a part of the Drug Discovery Technologies Subscription Service, provides an overview and outlook for the market. This study has been segmented into Proteomics Array Consumables Markets, including both planar and bead-based arrays, and Proteomics Array Instrumentation Markets, including stand-alone, detection, printing, and processing instrumentation. This research includes detailed market opportunities and industry trends that have been evaluated following extensive discussions with market participants.
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.